Oramed Pharmaceuticals Inc.

NASDAQ:ORMP

Biotechnology

Healthcare
$3.89 +0.79%

+$0.03 today

Market cap
$169.16M
Beta
1.24
P/E (TTM)
1.4
EPS (TTM)
$2.70
Dividend yield
6.54%
52W Low $1.98High $5.01

Volume 0.16M

Average 0.16M

ORMP Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Oramed Pharmaceuticals Inc.NASDAQ: ORMP

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin dips below year-ago levels

Q1 FY2026 selling, general & admin of $2.07M fell 10.5% year over year, behind the +21.4% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 43.9% from the prior quarter. Over 3 fiscal years it compounded at -17.7% a year.

Context

  • Selling, general & admin amounted to 436.0% of revenue in FY2025.
  • Selling, general & admin increased in 1 of the last 3 fiscal years.

What to watch

Whether selling, general & admin reaches the consensus estimate from 1 analysts of $4.85M (-44.4%) for the fiscal year ending Dec 2026, a slowdown from the +35.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.07M-43.9% QoQ
Last fiscal yearDec 2025
$8.72M+35.0% YoY
LTMMar 2026
$8.48M+21.4% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-10.5%-100.0%-89.5 pp
1 year+35.0%-44.4%-79.5 pp
3-year CAGR-17.7%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
8.72M USD
Year-over-year change
+35.0%
4-year CAGR
+10.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How ORMP compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +21.4% is the 2nd highest of 11, against a peer median of -8.0%.
  • Over three fiscal years its annual growth of -17.7% compares with a peer median of -1.5%.
ORMP Competitors
Selling, General & Admin for ORMP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
COYACoya Therapeutics, Inc.LTM Mar 2026$6.7B USD+73001.9%+33.2%84342.9%
MGNXMacroGenics, Inc.LTM Mar 2026$38.15M USD-27.9%-12.7%24.3%
OVIDOvid Therapeutics Inc.LTM Mar 2026$24.75M USD-6.4%-9.4%347.5%
IMAImageneBio IncLTM Mar 2026$21.2M USD-9.1%-2.3%—
CNTBConnect Biopharma Holdings LimitedFY2025$20.34M USD+5.8%-0.8%31781.3%
STTKShattuck Labs, Inc.LTM Mar 2026$17.37M USD-6.9%-4.3%1736.5%
KLRSKalaris Therapeutics IncLTM Mar 2026$15.32M USD-41.8%+90.0%—
IFRXInflaRx N.V.LTM Mar 2026€14.24M EUR-27.6%+7.0%48538.7%
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$8.48M USD+21.4%-17.7%—
CNTXContext Therapeutics Inc.LTM Mar 2026$8.11M USD+9.0%+0.2%—
CLNNClene Inc.LTM Mar 2026$7.9M USD-34.1%-17.0%5897.0%
Peer median (excluding ORMP) —-8.0%-1.5%5897.0%

Competitors are the stored peer set for ORMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Aug 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.7M2.7M1.34M02M
Cost of Revenue000193K1.99M
Gross Profit2.7M2.7M1.34M(193K)13K
Gross Margin100.0%100.0%100.0%—0.7%
Research & Development20.99M27.64M8.97M6.32M6.38M
Selling, General & Admin5.94M15.66M8.14M6.46M8.72M
Operating Expenses26.93M43.3M17.11M12.78M15.1M
Depreciation & Amortization77K3.62M196K193K121K
EBITDA(25.04M)(36.98M)7.32M(14.87M)75.45M
EBITDA Margin-926.3%-1368.0%546.3%—3772.2%
Operating Income(24.22M)(40.6M)(15.77M)(12.78M)(15.09M)
Operating Margin-896.2%-1502.0%-1176.8%—-754.4%
Interest Income347K3.57M8.03M02.37M
Interest Expense6K03.58M853K0
Other Income / Expenses893K2.93M20.86M(3.14M)90.41M
Income Before Tax(22.99M)(37.66M)5.09M(15.92M)75.32M
Pre-Tax Margin-850.5%-1393.4%379.7%—3766.2%
Income Tax Expense(2.88M)100K03.18M11.31M
Net Income(22.24M)(37.76M)5.53M(19.1M)64.05M
Net Margin-822.7%-1397.1%412.3%—3202.5%
EPS (Basic)(0.78)(0.97)0.14(0.47)1.53
EPS (Diluted)(0.78)(0.97)0.14(0.47)1.50
Weighted Avg Shares28.47M39M40.32M40.83M41.4M
Weighted Avg Shares (Diluted)28.47M39M40.57M40.83M42.42M

Oramed Pharmaceuticals Inc.

NASDAQ:ORMP

Intrinsic Alpha fair value

Locked

Current Price

$3.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.